// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

The Risk of Myocardial Infarction in Systemic Sclerosis: A Population-Based Study

Eric Sayre - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Myocardial infarction

N/A

Use of Antibiotics and Subsequent Risk of Systemic Lupus Erythematous: A Matched Case-Control Study

Mehyar Etminan - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

A Delphi Exercise for Treatment Algorithms for Systemic Lupus Erythematosus

Douglas Smith - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis.

Mary Bell - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers

Wayne Evans - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database

Peter Bhoi - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

What is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?

Regan Arendse - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

Development, Sensibility and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool

Joan Wither - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do Canadian Rheumatologists Actually Treat to Target Once a Biologic has been Initiated? An Analysis from a Prospective, Observational Registry

Mary Bell - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Ustekinumab

What is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and how do they Respond to Anti-TNF Treatment?

Proton Rahman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Concomitant Use of Oral vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in the Ontario Best Practice Research Initiative (OBRI) Cohort

Mohammad Movahedi - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

The Wolf in the Water: Lupus vs. Lymphoma

Lara Cooke - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Cyclophosphamide

The Quality and Continuity of Information between Primary Care Physicians and Rheumatologists

Carter Thorne - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterizing Referrals to Rheumatologists to Better Understand Care Management of Patients with Rheumatic Diseases

Carter Thorne - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Hypereosinophilia and Stroke as First Presentation of SLE

Aurore Fifi-Mah - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Eosinophilic granulomatosis with polyangiitis

Hydroxychloroquine

What is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort

Mohammad Movahedi - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

CMA Rheumatology Wait Time Benchmarks: The Need to Tame the Queue across the Continuum of Care

Sasha Bernatsky - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients

John Hanly - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Barriers Encountered in the Diagnosis of Pediatric Rheumatic Diseases in Kenya: A Focus Group Study

Tetiana Glushko - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Case Series of Macrophage Activation Syndrome in Adults with Rheumatic Diseases

Susan Barr - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Macrophage activation syndrome

N/A

Copyright © 2026. QuantiNova All rights reserved